De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate
Authors:
Open Access
- 11 June 2024
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 41 (8) , 3059-3075
Abstract
Introduction Switching disease-modifying therapy (DMT) may be considered for relapsing–remitting multiple sclerosis (RRMS) if a patient’s current therapy is no longer optimal. This was particularly important during the recent COVID-19 pandemic because of considerations around immune deficiency and impaired vaccine response associated with B cell-depleting DMTs. This real-world, single-center study aimed to evaluate change or decline in functional ability and overall disease stability in people with RRMS who were switched from B cell-depleting ocrelizumab (OCRE) to diroximel fumarate (DRF) because of safety concern related to the COVID-19 pandemic. Methods Adults with RRMS were included if they had been clinically stable for ≥ 1 year on OCRE. Data collected at baseline and 1 year post switch included relapse rate, magnetic resonance imaging (MRI), blood work for assessment of peripheral immune parameters, the Cognitive Assessment Battery (CAB), optical coherence tomography (OCT), and patient-reported outcomes (PROs). Results Participants (N = 25) had a mean (SD) age of 52 (9) years, and a mean (SD) duration of 26 (8) months’ treatment with OCRE before the switch to DRF. Median washout duration since the last OCRE infusion was 7 months (range 4–18 months). No participants relapsed on DRF during follow-up, and all remained persistent on DRF after 1 year. There were no significant changes in peripheral immune parameters, other than an increase in the percentage of CD19+ cells 1 year after switching (p < 0.05). Similarly, there were no significant changes in CAB, OCT, and PROs. Conclusion These preliminary findings suggest that transition to DRF from OCRE may be an effective treatment option for people with RRMS who are clinically stable but may need to switch for reasons unrelated to effectiveness. Longer follow-up times on larger samples are needed to confirm these observations.Keywords
Funding Information
- Biogen
This publication has 54 references indexed in Scilit:
- Emerging Approaches for Validating and Managing Multiple Sclerosis RelapseFrontiers in Neurology, 2017
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisNew England Journal of Medicine, 2017
- Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort studyThe Lancet Neurology, 2016
- Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsetsNeurology Neuroimmunology & Neuroinflammation, 2016
- Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosisMultiple Sclerosis Journal, 2013
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Optical Coherence Tomography (OCT): Imaging the Visual Pathway as a Model for NeurodegenerationNeurotherapeutics, 2011
- Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trialAnnals of Neurology, 2008
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple SclerosisNew England Journal of Medicine, 2008
- Prospective study on the relationship between infections and multiple sclerosis exacerbationsBrain, 2002